US Patent 8,632,760: Bimatoprost Eyelash-Growth Claims, Exclusivity, Litigation Risk, and Patent Landscape

US Patent 8,632,760 covers methods of increasing eyelash growth in humans by applying a bimatoprost solution to an eyelid margin. The commercially important limitations are topical administration, eyelash-growth results, once-daily use, and, in the narrower claims, a 0.03% w/v aqueous bimatoprost formulation. The patent does not claim bimatoprost as a compound or all ophthalmic uses. It claims a method of using bimatoprost for eyelash growth, eyelash hypotrichosis, or related cosmetic attributes.

The strongest commercial exposure is associated with products that reproduce the Latisse-type regimen: 0.03% bimatoprost applied once daily to the upper eyelid margin. Generic bimatoprost ophthalmic products approved for glaucoma or ocular hypertension do not automatically have approval for the eyelash-growth indication, but their sale can create method-of-use and induced-infringement issues depending on labeling, marketing, prescribing, and customer conduct.

What does US Patent 8,632,760 protect?

US 8,632,760 protects a therapeutic or cosmetic method involving:

A human subject.
A composition containing bimatoprost.
A solution or aqueous solution in the narrower claims.
Topical application to an eyelid margin.
Application to the upper eyelid margin in the independent claims.
Eyelash growth or increased eyelash length as the result.
Once-daily administration in several dependent claims.
A 0.03% w/v concentration in claims 10 through 26.
Optional increases in eyelash thickness, darkness, density, or growth rate.
Optional benzalkonium chloride in claim 25.

The patent does not require that the composition be sold under the Latisse brand. A competing product could fall within the claims if it contains bimatoprost and satisfies the relevant concentration, dosage, administration, and result limitations.

Claim architecture

Claim group	Principal limitations	Commercial significance
Claims 1-9	Bimatoprost solution applied to an eyelid margin to increase eyelash length, thickness, or darkness	Broadest method category; claim 1 centers on upper-margin application
Claims 10-18	0.03% w/v bimatoprost, topical eyelid-margin application, optional aqueous carrier, once-daily use, eyelash-loss treatment, and density	Closely tracks the Latisse-style product and regimen
Claims 19-26	0.03% w/v bimatoprost, increased eyelash growth or growth rate, once-daily administration, upper or lower margin, benzalkonium chloride, and comparison with no treatment	Adds functional-result and formulation limitations

How broad are the independent claims?

Claim 1 is broad in concentration and formulation terms. It requires a bimatoprost solution and application to the upper eyelid margin resulting in increased eyelash length. It does not expressly require 0.03% bimatoprost, benzalkonium chloride, an aqueous carrier, or once-daily dosing.

Claim 10 is narrower because it requires a 0.03% w/v bimatoprost solution. It also expressly requires upper-eyelid-margin application and increased eyelash length.

Claim 19 is also directed to 0.03% w/v bimatoprost but emphasizes increased eyelash growth. Claims 20 through 26 narrow that method through aqueous formulation, once-daily dosing, increased growth rate, increased density, eyelid-margin location, and benzalkonium chloride.

What constitutes infringement?

A product or regimen would present the clearest literal-infringement risk if it satisfies the following elements:

It contains bimatoprost.
It is used in a human.
It is applied topically to an eyelid margin.
The relevant claim requires, and the product uses, 0.03% w/v bimatoprost.
The application is once daily where required by the asserted claim.
The intended or actual result is longer, thicker, darker, denser, or faster-growing eyelashes.

For method claims, infringement generally turns on performance or direction of the claimed method, not merely possession of bimatoprost. A generic ophthalmic product labeled only for intraocular-pressure reduction presents a different analysis from a product marketed for eyelash growth.

Which claims are commercially strongest?

Claims 10, 14, 16, 19, 20, 23, and 25 are the most commercially relevant because they map closely to a practical eyelash-growth product.

Claim	Key limitation	Assessment
1	Bimatoprost solution applied to upper eyelid margin; increased eyelash length	Broad scope, but potentially vulnerable to prior-art and written-description attacks
3	At least once-daily application	Useful against daily-use regimens, but narrow
4	Once-daily application	Strong product-label alignment
10	0.03% w/v bimatoprost solution; upper-margin application; increased length	Core Latisse-type claim
12	Dermatologically acceptable carrier	Narrows the formulation requirement
13	Aqueous solution applied to upper and lower margins	Potentially useful for aqueous products
14	Once-daily use	High commercial relevance
15	Treatment of eyelash loss	Relevant to hypotrichosis-focused products
16	Increased length, thickness, or darkness	Broadens the claimed result
19	0.03% w/v bimatoprost; increased eyelash growth	Core growth claim
20	Aqueous solution, once daily, increased growth rate	More demanding proof and claim-construction issues
22	Increased eyelash density	Narrower functional claim
25	Benzalkonium chloride	Formulation-specific protection
26	Increased length compared with no bimatoprost	Comparator limitation may create proof issues

Claims 5 and 8 repeat the eyelash-length limitation already present in claim 1. Claims 6 and 7 add thickness and darkness. Claim 9 combines length, thickness, and darkness but may be harder to prove because all three outcomes must be established.

Claim 18 is structurally unusual because it recites “a method for use in claim 10” rather than using conventional dependent-claim language. Its enforceability would depend on the issued claim text, prosecution history, and claim-construction treatment. The same applies to any discrepancy between the supplied claim text and the official issued patent.

What formulations are protected by US 8,632,760?

The patent landscape is centered on a 0.03% w/v bimatoprost solution. The claims cover more than one formulation category:

0.03% bimatoprost solutions

Claims 10 and 19 expressly require 0.03% w/v bimatoprost. A product containing the same concentration and used for eyelash growth would face the closest claim comparison.

Aqueous formulations

Claims 13 and 20 require or contemplate an aqueous solution. An aqueous bimatoprost product may satisfy these limitations if it is applied to the claimed eyelid margin and used according to the required dosing schedule.

Benzalkonium chloride formulations

Claim 25 adds benzalkonium chloride. This limitation is important because benzalkonium chloride is used as a preservative in some ophthalmic formulations. A competing formulation without benzalkonium chloride would not literally satisfy claim 25, although it could still fall within broader claims.

Dermatologically acceptable carriers

Claim 12 covers bimatoprost in a dermatologically acceptable carrier. The carrier limitation could encompass more than a conventional ophthalmic vehicle, depending on the intrinsic evidence and prosecution history.

The patent does not appear to require a particular brand, bottle, applicator, preservative concentration, pH, viscosity, or packaging format in every claim. Those parameters may be relevant to separate formulation patents or to noninfringement positions.

When does US Patent 8,632,760 lose exclusivity?

US 8,632,760 issued on January 21, 2014. Its relevant patent-family term is generally associated with a September 2029 expiration date, subject to the official USPTO term calculation, any terminal disclaimer, and any patent-term adjustment. The patent should be treated as potentially enforceable through its operative expiration date unless the USPTO record or a court judgment establishes an earlier termination.

Milestone	Date or status
Patent number	US 8,632,760
Issue date	January 21, 2014
Technology	Bimatoprost eyelash-growth methods
Principal commercial product	Latisse, bimatoprost ophthalmic solution 0.03%
Expected term horizon	September 2029, subject to official term calculation
Patent type	Method-of-use patent
Compound exclusivity	Not claimed by this patent
Formulation exclusivity	Limited to the formulation features expressly recited in particular claims

Patent expiration does not automatically eliminate all market barriers. Separate patents, regulatory exclusivity, trade secrets, trademarks, device rights, and manufacturing know-how may continue to affect market entry.

What is the FDA and Orange Book status?

Latisse is associated with FDA New Drug Application No. 022369 and was approved for hypotrichosis of the eyelashes. The FDA labeling directs application of one drop nightly to the skin of the upper eyelid margin using the supplied applicator. The label warns against application to the lower eyelid and against reuse of applicators. [1]

The Orange Book is the controlling source for patents submitted to FDA in connection with an approved drug application. A patent listing does not itself establish validity or infringement. It identifies patent information submitted by the NDA holder and can affect the timing and certification obligations of an abbreviated new drug application.

For a generic applicant, the principal regulatory questions are:

Whether the ANDA references the Latisse NDA or relies on another approval pathway.
Whether the applicant seeks the eyelash-growth indication.
Whether the applicant files a Paragraph IV certification against an Orange Book-listed patent.
Whether the applicant uses a section viii statement to omit a patented method of use.
Whether the product labeling, promotional materials, or distribution practices create induced-infringement exposure.

A generic bimatoprost ophthalmic solution approved for glaucoma or ocular hypertension can potentially use a carve-out label that omits eyelash-growth language. That strategy reduces, but does not eliminate, patent risk.

How do Paragraph IV challenges affect this patent?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product. If the NDA holder receives proper notice, filing a patent-infringement action within the statutory period can trigger a 30-month stay of ANDA approval under the Hatch-Waxman Act. [2]

For US 8,632,760, the principal Paragraph IV theories would likely include:

Noninfringement

A generic applicant could argue that its label does not direct eyelash-growth use, its concentration differs from 0.03% w/v, or its product does not instruct application to the eyelid margin.

Anticipation

The applicant could argue that earlier publications or clinical evidence disclosed bimatoprost for eyelash growth, including the relevant concentration, administration site, frequency, and result.

Obviousness

The principal obviousness theory would combine prior knowledge of bimatoprost's prostamide or prostaglandin-related effects with clinical or cosmetic observations concerning eyelash growth. The patent owner would respond that the claimed eyelash-growth method, dosing regimen, and observed cosmetic effects were not predictable from the prior art.

Written description and enablement

The broader claims cover bimatoprost solutions without always specifying concentration or carrier. An accused infringer could challenge whether the patent adequately supports the full breadth of those claims or enables the claimed range of formulations and administration methods.

Double patenting

Because the bimatoprost eyelash-growth patent family includes related applications and continuations, obvious-type double-patenting issues and terminal disclaimers are important. The prosecution history must be reviewed before calculating the effective term or assessing validity.

Which companies are challenging bimatoprost eyelash-growth exclusivity?

The competitive threat is broader than a single named Paragraph IV challenger. It includes:

Generic manufacturers of bimatoprost ophthalmic solution 0.03%.
Companies selling private-label eyelash-growth products.
Compounding pharmacies preparing bimatoprost for non-approved cosmetic use.
Developers of alternative prostaglandin analogs or prostamide analogs.
Manufacturers using different concentrations, preservatives, delivery vehicles, or applicators.
Companies pursuing cosmetics that avoid bimatoprost and rely on peptides, botanical ingredients, or conditioning agents.

Generic bimatoprost ophthalmic products are not necessarily substitutes for an FDA-approved eyelash-growth product. Their regulatory labeling and promotional conduct determine whether they compete directly with Latisse or only with glaucoma products.

What litigation and settlement risks affect the patent?

The relevant litigation risk has two layers.

First, an ANDA applicant may challenge the patent through Hatch-Waxman litigation. The dispute would focus on claim scope, the approved use, the proposed label, and validity.

Second, a company may launch a product without seeking the patented eyelash-growth indication. In that case, the patent owner could pursue induced-infringement or contributory-infringement theories based on advertising, sales materials, customer instructions, pharmacy practices, social-media promotion, or physician prescribing behavior.

Settlement agreements can delay or limit generic entry through an agreed launch date, licensed entry, supply arrangements, or restrictions on the indication. Any settlement involving a first Paragraph IV filer may also affect 180-day generic exclusivity. A public patent number alone does not establish that a settlement exists. The relevant evidence is the court docket, FDA settlement reporting, and any FTC or DOJ filing.

How strong is the patent estate for Latisse?

The estate is strongest where a competitor replicates all of the following:

Bimatoprost rather than another eyelash-growth active.
A 0.03% w/v concentration.
A solution or aqueous ophthalmic formulation.
Once-daily application.
Application to the upper eyelid margin.
Marketing for increased eyelash length, density, thickness, darkness, or growth rate.

The estate is weaker against:

Products that omit bimatoprost.
Products marketed solely for non-eyelash indications.
Products using a different active ingredient.
Products with materially different concentration or dosing instructions.
Cosmetics that do not claim or direct eyelash growth.
Products supported by a label that excludes the patented method of use.

The broadest claims may face greater validity scrutiny because they cover a large range of bimatoprost solutions and eyelash-growth outcomes. The narrower 0.03% and once-daily claims may be easier to prove against a directly competing Latisse-type product but may also be more vulnerable to specific prior-art references.

What generic launch scenarios exist?

Launch scenario	Patent risk	Commercial outcome
Generic glaucoma product with no eyelash-growth indication	Moderate, mainly conduct-dependent	May enter ocular-hypertension market without directly competing with Latisse
Generic product with a section viii carve-out	Lower than full-label launch	Cannot lawfully market the carved-out patented use through its approved label
Generic product with full eyelash-growth indication before patent expiry	High	Likely Paragraph IV litigation and possible 30-month stay
Off-label or compounded bimatoprost sold for eyelash growth	High conduct-dependent risk	Exposure depends on labeling, promotion, dispensing, and formulation
Non-bimatoprost eyelash-growth product	Lower under this patent	May face separate patents or consumer-product regulation
Post-expiration full-label generic	Lower under this patent	Remaining barriers may include other patents, regulatory requirements, and brand loyalty

How does US 8,632,760 compare with competing patent rights?

US 8,632,760 is narrower than a compound patent because it does not claim bimatoprost itself. It is also narrower than a broad composition patent because most claims require a particular use and, in claims 10 through 26, a particular concentration.

Its value is therefore use-specific. A competitor can avoid direct infringement by changing the active ingredient or avoiding the claimed eyelash-growth instructions. A competitor that keeps bimatoprost, 0.03% concentration, once-daily dosing, and upper-margin application has a substantially narrower design-around path.

Separate patent rights may cover:

Bimatoprost synthesis and purification.
Ophthalmic formulations.
Preservative systems.
Applicators and delivery devices.
Alternative concentrations.
Treatment of glaucoma or ocular hypertension.
Other prostaglandin analogs for eyelash growth.
Manufacturing processes and quality-control methods.

Key Takeaways

US 8,632,760 is a method-of-use patent for bimatoprost-assisted eyelash growth in humans.
Claims 10 and 19 are the central 0.03% w/v claims.
Once-daily upper-eyelid-margin application presents the clearest infringement scenario.
The patent covers eyelash length and, in narrower claims, thickness, darkness, density, and growth rate.
It does not claim bimatoprost as a compound.
A glaucoma-only generic label is materially different from a full eyelash-growth label.
Paragraph IV litigation would likely focus on claim construction, prior art, obviousness, written description, and the applicant's proposed label.
The patent's expected term horizon is September 2029, subject to the official USPTO term record.
Products using different actives have a stronger design-around position than products using 0.03% bimatoprost for the Latisse regimen.
Separate Orange Book patents, formulation rights, regulatory exclusivity, and trade-secret protections must be assessed independently.

FAQs About US Patent 8,632,760 and Bimatoprost Eyelash Products

Does US 8,632,760 cover generic bimatoprost for glaucoma?

Not automatically. The patent covers specified methods of applying bimatoprost to an eyelid margin for eyelash growth. A glaucoma-only product may avoid literal infringement if its label and commercial conduct do not direct the patented use.

Can a company avoid the patent by using less than 0.03% bimatoprost?

A lower concentration may avoid claims expressly requiring 0.03% w/v, but it may not avoid broader claims that do not specify concentration. The complete claim set and prosecution history must be analyzed.

Does applying bimatoprost to the lower eyelid avoid infringement?

No. Claims 2, 11, and 24 expressly address lower-eyelid-margin application. Lower-margin use may still infringe a claim that includes that limitation.

Are eyelash serums without bimatoprost covered by this patent?

Generally, no. The claims require bimatoprost. A non-bimatoprost serum would need to be evaluated against separate patents, trademarks, regulatory rules, and other intellectual-property rights.

Does patent expiration authorize an unapproved eyelash-growth product?

No. Patent expiration removes the patent barrier for the expired claims. FDA approval, labeling, manufacturing, prescription, pharmacy, and advertising requirements remain separate regulatory issues.

References

U.S. Food and Drug Administration. (2008). Latisse (bimatoprost ophthalmic solution) 0.03% prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Patent and Trademark Office. (2014). U.S. Patent No. 8,632,760: Methods of increasing eyelash growth using bimatoprost. USPTO.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
U.S. Food and Drug Administration. (2024). Patent and exclusivity information. FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003207843	⤷ Start Trial
Australia	2008203212	⤷ Start Trial
Australia	2010227111	⤷ Start Trial
Australia	2012261499	⤷ Start Trial
Australia	2013208002	⤷ Start Trial
Canada	2475106	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,632,760

Summary for Patent: 8,632,760